Peptide compounding status.

An FDA advisory panel voting to recommend a peptide is not the same as a pharmacy being allowed to make it. Those are separate steps, and most coverage treats them as one. This page tracks where each peptide actually stands.

The categories below are positions on the FDA's list of substances that have been put forward for compounding and are still being worked through. That is not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs — not that it is on the list.

• Emideltide
  An FDA panel said noNever put forward to FDA

  FDA reviewed it for Opioid withdrawal, chronic insomnia, and narcolepsy

  Last change 2026-07-24

  The advisory panel voted against Emideltide. FDA has not said whether it will consider it again, and…

• BPC-157
  An FDA panel said yes — nothing has changed yetNever put forward to FDA

  FDA reviewed it for Ulcerative colitis

  Last change 2026-07-23

  FDA has not said whether it will move BPC-157 into Category 1 while it decides. It also has not star…

• KPV
  An FDA panel said yes — nothing has changed yetNever put forward to FDA

  FDA reviewed it for Wound healing and inflammatory conditions

  Last change 2026-07-23

  FDA has not said whether it will move KPV into Category 1 while it decides, and has not started form…

• MOTS-c
  An FDA panel said yes — nothing has changed yetNever put forward to FDA

  FDA reviewed it for Obesity and osteoporosis

  Last change 2026-07-23

  FDA has not said whether it will move MOTS-c into Category 1 while it decides, and has not started f…

• TB-500
  An FDA panel said yes — nothing has changed yetNever put forward to FDA

  FDA reviewed it for Wound healing

  Last change 2026-07-23

  FDA has not said whether it will move TB-500 into Category 1 while it decides, and has not started f…

• ARA-290
  Category 3 — not enough evidence sent inNever put forward to FDA

  Last change 2026-05-14

• GHRP-2
  Category 3 — not enough evidence sent inDepends on the route — see timeline

  Last change 2026-05-14

• GHRP-6
  Category 3 — not enough evidence sent inCategory 2 — FDA flagged a safety concern

  Last change 2026-05-14

• Glutathione
  Category 1 — under review, allowed for nowCategory 1 — under review, allowed for now

  Last change 2026-05-14

• Kisspeptin-10
  Category 2 — FDA flagged a safety concernNever put forward to FDA

  Last change 2026-05-14

• MGF
  Category 3 — not enough evidence sent inNever put forward to FDA

  Last change 2026-05-14

• MK-677
  Category 2 — FDA flagged a safety concernCategory 2 — FDA flagged a safety concern

  Last change 2026-05-14

• NAD+
  Category 1 — under review, allowed for nowNever put forward to FDA

  Last change 2026-05-14

• VIP
  Category 1 — under review, allowed for nowNever put forward to FDA

  Last change 2026-05-14

• GHK-Cu
  Depends on the route — see timelineNever put forward to FDA

  Last change 2026-05-05

  FDA has said it intends to consult its compounding advisory committee (the PCAC) about whether GHK-C…

• Argireline
  Never put forward to FDACategory 3 — not enough evidence sent in
• Epitalon
  Reviewed by FDA — see timelineNever put forward to FDA
• Gonadorelin
  Never put forward to FDACategory 1 — under review, allowed for now
• Ipamorelin
  Never put forward to FDACategory 2 — FDA flagged a safety concern
• Oxytocin
  Never put forward to FDACategory 1 — under review, allowed for now
• Semax
  Reviewed by FDA — see timelineNever put forward to FDA
• Sermorelin
  Never put forward to FDACategory 1 — under review, allowed for now
• Thymosin Alpha-1
  Never put forward to FDACategory 3 — not enough evidence sent in

Most recent check against a primary source: 2026-08-25.